- Home
- CGNT vs AUTL Comparison
CGNT vs AUTL Comparison
Compare CGNT & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CGNT | AUTL |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | Israel | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 592.2M | 596.2M |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | CGNT | AUTL |
|---|---|---|
| Price | $8.62 | $1.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $13.50 | $8.50 |
| AVG Volume (30 Days) | 657.1K | ★ 1.9M |
| Earning Date | 06-10-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | $13.73 | $80.32 |
| Revenue Next Year | $10.45 | $53.96 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $6.29 | $1.18 |
| 52 Week High | $12.31 | $2.58 |
Technical Indicators
Market Signals| Indicator | CGNT | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 46.39 | 41.72 |
| Support Level | $7.87 | $1.37 |
| Resistance Level | $9.07 | $2.07 |
| Average True Range (ATR) | 0.32 | 0.09 |
| MACD | -0.00 | -0.07 |
| Stochastic Oscillator | 42.56 | 13.16 |
Price Performance
Historical ComparisonAbout CGNT Cognyte Software Ltd.
Cognyte Software Ltd provides security analytics software that empowers governments and enterprises with Actionable Intelligence. Its interface software is designed to help customers accelerate and improve the effectiveness of investigations and decision-making.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.